XBiotech Inc. (NASDAQ:XBIT)’s share price traded up 5.6% on Tuesday . The company traded as high as $15.34 and last traded at $15.27, with a volume of 208,024 shares trading hands. The stock had previously closed at $14.46.

XBIT has been the subject of a number of research reports. Zacks Investment Research lowered XBiotech from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 20th. Noble Financial restated a “buy” rating and set a $30.00 price objective (up from $24.00) on shares of XBiotech in a research report on Tuesday, June 28th.

The firm’s market capitalization is $492.47 million. The company has a 50 day moving average price of $15.87 and a 200 day moving average price of $12.85.

In other news, Director W Thorpe Mckenzie bought 20,000 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was bought at an average price of $13.96 per share, for a total transaction of $279,200.00. Following the completion of the transaction, the director now directly owns 3,898,600 shares in the company, valued at approximately $54,424,456. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.